Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxi...
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine
- Conditions
- Interventions
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Nathan Bahary, MD
- Target Recruit Count
- 104
- Registration Number
- NCT01978184
- Locations
- 🇺🇸
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2018-11-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT01941095
- Locations
- 🇬🇷
Laiko General Hospital; Dept. of Pathophysiology-Uni of Athens, Athens, Greece
🇬🇷Uni Hospital of Ioannina; Rheumatology, Ioannina, Greece
🇬🇷General Hospital of Thessaloniki HIPPOKRATIO; Clinical Immunology Unit,2nd Dept of Internal Medicine, Thessaloniki, Greece
Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2014-08-28
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 4
- Registration Number
- NCT01833845
- Locations
- 🇫🇷
Hospital St. Joseph, Marseille, France
🇫🇷Cochin Hospital, Paris, France
Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-04-10
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 13
- Registration Number
- NCT01828476
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients
- First Posted Date
- 2013-02-06
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Hospital for Special Surgery, New York
- Target Recruit Count
- 11
- Registration Number
- NCT01784523
- Locations
- 🇺🇸
Hospital for Special Surgery, New York, New York, United States
Antibiotics and Hydroxychloroquine in Crohn's
- Conditions
- Interventions
- First Posted Date
- 2013-02-04
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- Royal Liverpool University Hospital
- Target Recruit Count
- 59
- Registration Number
- NCT01783106
- Locations
- 🇬🇧
Royal Liverpool and Broadgreen Unversity Hospitals Trust, Liverpool, Merseyside, United Kingdom
To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)
- First Posted Date
- 2013-01-15
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 202
- Registration Number
- NCT01768572
- Locations
- 🇺🇸
Investigational Site Number 840033, Fort Lauderdale, Florida, United States
🇺🇸Investigational Site Number 840150, Lansing, Michigan, United States
🇺🇸Investigational Site Number 840022, Dallas, Texas, United States
The Effect of Hydroxychloroquine Treatment in Hashimoto's Thyroiditis
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2014-04-23
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT01760421
- Locations
- 🇨🇳
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)
- Conditions
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 546
- Registration Number
- NCT01709578
- Locations
- 🇺🇸
Investigational Site Number 840018, Idaho Falls, Idaho, United States
🇺🇸Investigational Site Number 840058, Columbia, South Carolina, United States
🇺🇸Investigational Site Number 840124, Clarksburg, West Virginia, United States
Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2017-09-07
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT01689987
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.